# SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

> **NCT05319574** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 46 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05319574
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-24
- **Primary completion:** 2023-06-25
- **Final completion:** 2026-05-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319574, "SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05319574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*